Sarah Ketterer
Causeway Capital Management
Sarah Ketterer AstraZeneca PLC stake
total: 372
Causeway Capital Management AZN-OLD trades
- Total transactions:
- 20
- New positions:
- 1
- Sold out:
- 1
- Added:
- 11
- Reduced:
- 7
- Held since:
- 2021 Q2
- Held for:
- 19 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q2 report, Sarah Ketterer doesn't hold any AstraZeneca PLC (AZN-OLD) shares. To date, the estimated cost basis is nearly $66.4 for "buy" trades and estimated average "sell" price is $87.5. Causeway Capital Management first purchased AZN-OLD in 2021 Q2, initially acquiring 169,783 shares. Since the initial investment in AstraZeneca PLC (AZN-OLD), Causeway Capital Management has made 19 more transactions.
When did Sarah Ketterer sell AstraZeneca PLC (AZN-OLD)?
Sarah Ketterer sold off the entire AstraZeneca PLC (AZN-OLD) position in 2026 Q1.
When did Sarah Ketterer buy AstraZeneca PLC (AZN-OLD)?
Sarah Ketterer first invested in AstraZeneca PLC (AZN-OLD) in 2021 Q2 at the reported quarter-end price of $59.90 per share.
What's the cost basis of Causeway Capital Management's AZN-OLD stake?
The estimated cost basis for AstraZeneca PLC (AZN-OLD) stake is around $66.40 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $66.40
- Weighted AVG sell price:
- $87.50
Sarah Ketterer's historical trades in AstraZeneca PLC
20 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.00%
|
0
|
$91.93
|
|
-100% (-1,010,898)
|
-1.28%
|
|
2025 Q4
|
1.28%
|
1,010,898
|
$91.93
|
$92,931,891
|
-5.29% (-56,473)
|
-0.07%
|
|
2025 Q3
|
1.08%
|
1,067,371
|
$76.72
|
$81,888,708
|
+11.95% (+113,923)
|
+0.12%
|
|
2025 Q2
|
1.05%
|
953,448
|
$69.88
|
$66,626,954
|
+11.14% (+95,561)
|
+0.11%
|
|
2025 Q1
|
1.32%
|
857,887
|
$73.50
|
$63,054,666
|
+3.13% (+26,017)
|
+0.04%
|
|
2024 Q4
|
1.24%
|
831,870
|
$65.52
|
$54,504,114
|
+69.62% (+341,431)
|
+0.51%
|
|
2024 Q3
|
0.94%
|
490,439
|
$77.91
|
$38,210,109
|
+8.84% (+39,851)
|
+0.08%
|
|
2024 Q2
|
0.96%
|
450,588
|
$77.99
|
$35,141,382
|
-9.24% (-45,888)
|
-0.09%
|
|
2024 Q1
|
0.88%
|
496,476
|
$67.75
|
$33,636,232
|
+7.76% (+35,754)
|
+0.06%
|
|
2023 Q4
|
0.79%
|
460,722
|
$67.35
|
$31,029,651
|
+29.70% (+105,501)
|
+0.18%
|
|
2023 Q3
|
0.63%
|
$67.72
|
+34.38% (+90,875)
|
|||
|
2023 Q2
|
0.50%
|
$71.57
|
-18.34% (-59,357)
|
|||
|
2023 Q1
|
0.54%
|
$69.41
|
+12.16% (+35,083)
|
|||
|
2022 Q4
|
0.57%
|
$67.80
|
-5.25% (-15,993)
|
|||
|
2022 Q3
|
0.47%
|
$54.84
|
-8.77% (-29,284)
|
|||
|
2022 Q2
|
0.55%
|
$66.07
|
-18.19% (-74,258)
|
|||
|
2022 Q1
|
0.65%
|
$66.34
|
+23.51% (+77,683)
|
|||
|
2021 Q4
|
0.42%
|
$58.25
|
-4.77% (-16,539)
|
|||
|
2021 Q3
|
0.47%
|
$60.06
|
+104.39% (+177,228)
|
|||
|
2021 Q2
|
0.21%
|
$59.90
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.